Co-locating trial and commercial manufacturing eases tech transfer and cuts cycle times, Aesica

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmacology

Moving its clinical manufacturing operations to its API and drug site in Queenborough has reduced the risk of problems during tech transfer and cut cycle times according to UK CMO Aesica.

Aesica moved its clinical trial material manufacturing operations from Nottingham to a new purpose built centre late last month, citing a desire to increase capacity and better integrate this part of its business with its commercial production operations.

Managing director Ian Muir told us the centre “will focus on formulation development, analytical method development and stability in support of projects in pre commercial Phase I-III of development​.”

He added that: “By co locating the facility at our largest API and Finished Dose commercial site we would hope to drive greater integration with the commercial site, reduce the risks of technology transfer for customers and reduce the overall development cycle time​.”

Aesica was acquired by Consort Medical in 2014. The deal was driven by Consort’s desire to expand its inhalable and injectable drug manufacturing unit, Bespak.


Unlike the new facility that Aesica owns outright, the previous clinical manufacturing facility located at a leased unit at Nottingham’s BioCity biotech and drug production hub.

Aesica – which took on the lease for the Nottingham site when it acquired clinical manufacturing specialist R5 Pharmaceuticals​ in 2010 – shared the facility with spray-drying technology firm Upperton.

Upperton CEO Richard Johnson told us his firm had maintained a presence in BioCity at the former Aesica site despite having relocated to Nottingham’s MediCity complex in September last year.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Related suppliers

Follow us


View more